Why this speculative ASX stock could rocket 70%

Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this …

| More on:
A young man wearing a black and white striped t-shirt looks surprised.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors with a high tolerance for risk might want to take a look at the speculative ASX stock in this article.

After all, the team at Bell Potter believes that it could deliver big returns for investors over the next 12 months if everything goes to plan.

Which speculative ASX stock?

The stock in question is Opthea Ltd (ASX: OPT).

It is a biopharmaceutical company developing novel therapies that aim to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases. This includes wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate is sozinibercept. It is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies. The trial aims to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

What is the broker saying?

Bell Potter notes that the company has released an investor presentation with some new data. This includes an update on its phase three trial, which Bell Potter was pleased with. It said:

We take further confidence from the Ph3 patient populations being broadly similar to those included in the previous Ph2b trial. There was only one formal change to entry criteria in the Ph3 trials (the exclusion of RAP patients), with other differences in baseline characteristics being relatively small increases in the proportion of better responding occult patients (+10%) and PCV patients (+6-8%), which provide greater conviction that the ongoing Ph3 trials will replicate the positive BCVA outcomes seen in the Ph2b.

This is good news for shareholders because if the company is successful with its trials, it could open the door to significant revenues. It explains:

Over a million older Americans currently live with wet AMD, and a further ~200k are diagnosed each year as the population ages. The use of injectable drugs to treat wet AMD has become very well established over the last ~15 years, with the market now >US$5b in the US alone (combining Lucentis/Eylea/Vabysmo sales). The opportunity for sozinibercept is undoubtedly a lucrative one, with genuine blockbuster potential even if only a fraction of the current market is captured.

Big return potential

Bell Potter has reaffirmed its speculative buy rating and $1.30 price target on the ASX stock.

Based on its current share price of 75 cents, this implies potential upside of 73% for investors over the next 12 months.

Commenting on its bullish view of the stock, the broker concludes:

We continue to view the stock as having a favourable risk-reward profile, with substantial upside opportunity in the event of successful Ph3 results. There has been intense pharma competition in recent quarters among the incumbent anti-VEGF-A competitors (Regeneron, Roche, biosimilars), which in our view heightens the strategic appeal of sozinibercept to these parties as a means of diversifying and expanding their blockbuster ophthalmic franchises.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Speculative

Father and daughter with hands on a small plant.
Growth Shares

Could this be a millionaire-maker ASX growth stock at 67 cents?

I'll be keeping a close eye on this ASX fintech.

Read more »

Speculative

Bell Potter says this speculative ASX stock can rocket 40%

If you have a high tolerance for risk, then it could be worth checking out Vitrafy Life Sciences Ltd (ASX:…

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Speculative

Why this speculative ASX stock could rise ~50%

Bell Potter sees potential for big returns over the next 12 months.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Speculative

These speculative ASX mining stocks could rise 85%+

Bell Potter has put speculative buy ratings on these stocks this morning.

Read more »

surprised asx investor appearing incredulous at hearing asx share price
Speculative

'Blockbuster opportunity': This speculative ASX stock could rise 70%

Bell Potter thinks exciting times could be around the corner for this buy-rated high risk stock.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Healthcare Shares

Buy this small cap ASX stock with a 'lucrative opportunity'

Bell Potter thinks this speculative stock could have major upside thanks to its US market opportunity.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Speculative

Broker says this speculative ASX stock could rise over 200%

This high risk option could have major upside according to analysts.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Speculative

Meet the speculative ASX stock tipped to rise 180%

Bell Potter thinks this share could almost triple in value.

Read more »